e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 48

Relaxin reverses inflammatory and immune signals in aged hearts

Brian Martin; Beth A. Gabris-Weber; Rajiv P. Reddy; Guillermo Romero; Ansuman Chattopadhyay; Guy Salama · 2018 · PLoS ONE

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: 'Healthy' aging drives structural and functional changes in the heart including maladaptive electrical remodeling, fibrosis and inflammation, which lower the threshold for cardiovascular diseases such as heart failure (HF) and atrial fibrillation (AF). Despite mixed results in recent clinical trials, Relaxin-therapy for 2-days could reduce mortality by 37% at 180-days post-treatment, in patients with acute decompensated HF. Relaxin's short life-span (hours) but long-lasting protective actions led us to test the hypothesis that relaxin acts at a genomic level to reverse maladaptive

Abstract by Brian Martin; Beth A. Gabris-Weber; Rajiv P. Reddy; Guillermo Romero; Ansuman Chattopadhyay; Guy Salama, PLoS ONE (2018) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1371/journal.pone.0190935